Search results
Results From The WOW.Com Content Network
In France, Serotonin was the best-selling fiction book in the week it was released. [9] Within three days of its publication, it had sold 90,000 copies. [ 10 ] The release was considered a national event, coming as it did the same month Houellebecq was awarded the Legion of Honour .
Serotonin (/ ˌ s ɛr ə ˈ t oʊ n ɪ n, ˌ s ɪər ə-/) [6] [7] [8] or 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter.Its biological function is complex, touching on diverse functions including mood, cognition, reward, learning, memory, and numerous physiological processes such as vomiting and vasoconstriction.
They act by antagonizing the α 2-adrenergic receptor and certain serotonin receptors such as 5-HT 2A and 5-HT 2C, [1] but also 5-HT 3, [1] 5-HT 6, and/or 5-HT 7 in some cases. By blocking α 2 -adrenergic autoreceptors and heteroreceptors , NaSSAs enhance adrenergic and serotonergic neurotransmission in the brain involved in mood regulation ...
Dual serotonin and norepinephrine reuptake inhibition resides in different enantiomers for arylthiomethyl morpholine scaffold. [41] Possible drug candidates with dual serotonin and norepinephrine reuptake inhibitory activity have also been derived from piperazine, 3-amino-pyrrolidine and benzylamine templates. [42]
Higher dosage does, however, increase the incidence and severity of adverse events associated with excessive 5-HT re-uptake inhibition. [ 6 ] Figure 2 Inhibition of re-uptake transport proteins, e.g. SERT, results in increased concentration of neurotransmitters, e.g. 5-HT, in the synaptic cleft, leading to improvement of depression symptoms
The pharmacology of antidepressants is not entirely clear.. The earliest and probably most widely accepted scientific theory of antidepressant action is the monoamine hypothesis (which can be traced back to the 1950s), which states that depression is due to an imbalance (most often a deficiency) of the monoamine neurotransmitters (namely serotonin, norepinephrine and dopamine). [1]
It increases dopamine levels in the nucleus accumbens, blocks amphetamine-induced dopamine release in vitro, shows no effect on locomotor activity with acute or repeated administration except at a high dose, and enhances learning in animals. [3] [2] [5] CE-158 was first described by 2020. [5] It is closely related to CE-123, an earlier ...
In addition, the augmentation of a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor with lisdexamfetamine, a norepinephrine–dopamine releasing agent, recently failed to separate from placebo in phase III clinical trials of individuals with treatment-resistant depression, and clinical development was ...